Clinical Trial Update: Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR). [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluated whether the ultrasound contrast agent Optison alters pulmonary artery systolic pressure and pulmonary vascular resistance in pu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension

Drugs mentioned

• Optison

Snippet

Sponsor: GE Healthcare | Conditions: Pulmonary Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2012-08-24